By
Latest Stories
Don’t miss our hot and upcoming stories
Recursion Reports Promising Interim Data for AI-Designed CDK7 Inhibitor in Ovarian Cancer
Salt Lake City – December 9, 2024 Recursion (Nasdaq: RXRX), a leader in AI-powered drug…
Recursion Doses First Patient in Phase 1/2 Trial of REC-1245 for Biomarker-Enriched Solid Tumors and Lymphoma
Recursion (NASDAQ: RXRX), a cutting-edge clinical-stage TechBio company, has announced the successful dosing of the…
AI Drug Discovery Leaders Recursion and Exscientia Merge to Transform Drug Discovery
Recursion and Exscientia, two trailblazers in AI-driven drug discovery, have officially merged to form a…
NVIDIA Expands AI-Driven Drug Discovery with BioNeMo Framework
November 18, 2024 NVIDIA has launched a major initiative to scale AI-powered drug discovery through…